Literature DB >> 7149903

Desipramine plasma concentration and antidepressant response.

J C Nelson, P Jatlow, D M Quinlan, M B Bowers.   

Abstract

The relationship of desipramine hydrochloride plasma concentration and antidepressant response was determined in 30 depressed inpatients treated for three weeks with desipramine. All patients had a nondelusional unipolar depression, met DSM-III criteria for major depressive episode with melancholia, and had a Hamilton score of 18 or greater after one week of hospitalization without medication. Eighty-nine percent of the patients with plasma concentrations above 115 ng/mL responded, in contrast to 14% of those with concentrations below this level, a significant difference (Fisher's exact test, P less than .001). Ten initial nonresponders were converted to responders when dosage increase raised desipramine plasma concentration to 125 ng/mL or above. In clinical practice a plasma concentration of 125 ng/mL would be a useful guideline as a threshold above which desipramine is likely to be effective.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7149903     DOI: 10.1001/archpsyc.1982.04290120049010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  14 in total

Review 1.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

2.  Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.

Authors:  E Spina; C Gitto; A Avenoso; G M Campo; A P Caputi; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

3.  Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects.

Authors:  L H Price; D S Charney; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.

Authors:  Gisa Gerstenberg; Toshiaki Aoshima; Takashi Fukasawa; Keizo Yoshida; Hitoshi Takahashi; Hisashi Higuchi; Yoshiko Murata; Ritsuko Shimoyama; Tadashi Ohkubo; Tetsuo Shimizu; Koichi Otani
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

5.  Effects of electroconvulsive therapy and desipramine on neuroendocrine responses to the clonidine challenge test.

Authors:  M Coote; A Wilkins; E S Werstiuk; M Steiner
Journal:  J Psychiatry Neurosci       Date:  1998-05       Impact factor: 6.186

Review 6.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  Antidepressant failure: augmentation or substitution?

Authors:  R T Joffe; A J Levitt
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

8.  Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABAA receptors.

Authors:  Rebecca S Benham; Nishani B Hewage; Raymond F Suckow; Elif Engin; Uwe Rudolph
Journal:  Behav Brain Res       Date:  2017-06-03       Impact factor: 3.332

9.  Doxepin plasma concentrations in clinical practice. Could there be a pharmacokinetic explanation for low concentrations?

Authors:  P R Joyce; J R Sharman
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

10.  Neuronal monoamine reuptake inhibitors enhance in vitro susceptibility to chloroquine in resistant Plasmodium falciparum.

Authors:  A F Coutaux; J J Mooney; D F Wirth
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.